TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

Summary

This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.

Eligibility

Inclusion Criteria:

* Signed informed consent form.
* Diagnosis of stage IV non-small cell lung cancer.
* Male or female patients aged 18 years or older.
* Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.
* Patients who have received up to 3 cycles of atezolizumab at the screening visit.

Exclusion Criteria:

* Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.
* Known or suspected hypersensitivity to atezolizumab.
* Pregnant or breastfeeding women.

Conditions6

Browse More Trials